RESEARCH · TIRZEPATIDE · ISLET PHYSIOLOGY
Tirzepatide and the Islet: Beta-Cell Function, Insulin Sensitivity and Glucagon in Clamp and Meal-Test Studies
PurixLab’s Tirzepatide 10mg is a research vial of tirzepatide, a single peptide that activates both the GIP and GLP-1 receptors. Our earlier articles cover the SURPASS and SURMOUNT trial programmes, the imbalanced and biased receptor pharmacology and gastric emptying and appetite. This article looks inside the glucose-lowering effect itself: what physiological studies in people show about beta-cell function, insulin sensitivity and glucagon, and how much of the change can be explained by weight loss alone. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Three levers of glucose control
Blood glucose in type 2 diabetes reflects at least three processes: how much insulin the beta cells release in response to glucose, how well muscle, fat and liver respond to that insulin, and how strongly alpha cells keep releasing glucagon. Researchers measure these in different ways. The hyperinsulinaemic-euglycaemic clamp gives a direct measure of insulin sensitivity (the M value). Mixed-meal tests with mathematical modelling estimate insulin secretion and beta-cell glucose sensitivity. Large trials usually rely on fasting surrogates such as HOMA2-B for beta-cell function, HOMA2-IR for insulin resistance and the proinsulin-to-C-peptide ratio as a marker of beta-cell stress. The studies below use all three approaches, and the methods matter for how far each result can be pushed.
The mechanistic trial: clamp and meal tests
The most detailed study is a 28-week, double-blind phase 1 trial at two centres in Germany. People with type 2 diabetes on metformin were randomised 3:3:2 to tirzepatide 15 mg, semaglutide 1 mg or placebo once weekly; 117 were enrolled [1]. The primary endpoint was the clamp disposition index, which combines insulin secretion and sensitivity. With tirzepatide it rose by 1.9 units from a baseline of 0.3, while placebo showed essentially no change; the estimated treatment difference versus placebo was 1.92. Against semaglutide the difference was 0.84, reflecting greater gains in both total insulin secretion rate and clamp-measured insulin sensitivity. On meal testing, tirzepatide lowered glucose excursions with lower insulin and glucagon concentrations, and these effects were larger than with semaglutide [1].
A model-based re-analysis of the meal-test data added nuance. Tirzepatide reduced fasting glucose and total glucose area under the curve more than semaglutide, but the incremental rise after the meal did not differ significantly, so most of the extra effect came from lower fasting glucose. Insulin secretion at a fixed glucose level and insulin sensitivity improved more with tirzepatide, glucagon area under the curve fell more, and the estimated hepatic insulin-to-glucagon ratio changed little with either drug [2].
Is it just weight loss?
Weight loss on its own improves insulin sensitivity, so the obvious question is whether tirzepatide does anything beyond that. An exploratory analysis of the same trial related change in M value to change in body weight. With tirzepatide the correlation was R = -0.656; with semaglutide it was weaker, R = -0.268, and the slope of the relationship differed between drugs. The authors concluded that tirzepatide gave more insulin-sensitivity improvement per unit of weight lost [3].
Fasting-biomarker analyses point the same way. In the phase 2b trial against dulaglutide, regression models suggested that weight loss explained only 13% and 21% of the HOMA2-IR improvement in the 10 mg and 15 mg arms [4]. In the SURMOUNT-1 obesity trial, which enrolled 2,539 participants without diabetes, oral glucose tolerance test modelling found that improved insulin sensitivity tracked mostly with weight reduction, whereas improved beta-cell function was mostly associated with tirzepatide treatment itself [5]. A 12-week, single-arm Japanese study of 16 participants measured insulin sensitivity by clamp and found the glucose rate needed to hold euglycaemia rose from 3.21 to 5.16 mg/min per kg, with no significant relationship between that change and other clinical variables [6]. Being single-arm and small, it cannot separate drug from time or weight effects.
Beta-cell markers across the phase 3 programme
- SURPASS-1 (monotherapy, 478 participants). At 40 weeks, fasting proinsulin fell 49-55% and HOMA2-B (C-peptide) rose 77-92% across tirzepatide arms versus small changes with placebo; glucose-adjusted glucagon fell 37-44% [7].
- SURPASS-2 (versus semaglutide 1 mg, 1879 participants). HOMA2-B rose 96.9-120.4% with tirzepatide versus 84.0% with semaglutide, and HOMA2-IR fell 15.5-24.0% versus 5.1%. HbA1c and weight reductions were greater with tirzepatide in every baseline quartile of beta-cell function and insulin resistance [8].
- SURPASS J-mono (Japan, versus dulaglutide 0.75 mg, 636 participants). Over 52 weeks, HOMA2 sensitivity and beta-cell indices rose more with all tirzepatide arms, and HbA1c improved more regardless of whether baseline C-peptide was above or below the median [9]. A 48-person meal-test substudy found lower post-meal glucose, insulin, glucagon and C-peptide responses with tirzepatide than with dulaglutide [10].
Glucagon: suppressed after meals, preserved in hypoglycaemia
GIP can stimulate glucagon secretion, particularly at low glucose, which raised the question of how a GIP-receptor agonist would affect alpha cells. In the trials above, fasting and post-meal glucagon fell with tirzepatide [1,7,8]. A separate crossover study tested the other side: 42 people with type 2 diabetes received tirzepatide 15 mg or placebo for 12 weeks and then underwent a stepped hypoglycaemic clamp down to about 45 mg/dL. The rise in glucagon during hypoglycaemia did not differ between treatments, and growth hormone and adrenaline responses were also similar. Cortisol and noradrenaline responses were delayed and symptom scores at nadir were lower with tirzepatide, while the proportion of participants aware of hypoglycaemia did not differ [11].
What remains open
- Surrogates versus direct measures. Most data come from fasting HOMA indices and proinsulin ratios in post hoc analyses [7,8,9]; only one randomised trial used clamps and modelled meal tests [1].
- Sponsorship and authorship. The randomised studies were funded or co-authored by the manufacturer, and several analyses are exploratory [1,3].
- Durability. Whether beta-cell gains persist after treatment stops has not been tested in these designs; markers were measured on treatment, at 12 to 72 weeks [11,5].
- Which receptor does what. Clinical studies cannot separate GIP-receptor from GLP-1-receptor contributions; that question sits with receptor pharmacology and knockout models.
Tirzepatide 10mg at PurixLab
Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418-429. PubMed 35468322 · doi:10.1016/S2213-8587(22)00085-7
- Mather KJ, Mari A, Heise T, et al. Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. J Clin Endocrinol Metab. 2024;109(12):3046-3054. PubMed 38795393 · doi:10.1210/clinem/dgae319
- Mather KJ, Mari A, Weerakkody G, et al. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes Obes Metab. 2025;27(3):1507-1514. PubMed 39762971 · doi:10.1111/dom.16159
- Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. PubMed 33236115 · PMC7823251 · doi:10.1210/clinem/dgaa863
- Mari A, Stefanski A, van Raalte DH, et al. Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care. 2025;48(9):1622-1627. PubMed 40694530 · PMC12368374 · doi:10.2337/dc25-0763
- Yamaguchi Y, Kuwata H, Imura M, et al. Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes. Diabetologia. 2025;68(10):2151-2155. PubMed 40694059 · doi:10.1007/s00125-025-06493-5
- Lee CJ, Mao H, Thieu VT, et al. Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1). J Endocr Soc. 2023;7(5):bvad056. PubMed 37153701 · PMC10157777 · doi:10.1210/jendso/bvad056
- Frias JP, De Block C, Brown K, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. 2024;109(7):1745-1753. PubMed 38252888 · PMC11180500 · doi:10.1210/clinem/dgae038
- Hamamoto Y, Oura T, Hirase T. Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis. Diabetes Ther. 2025;16(4):717-729. PubMed 39951042 · PMC11926299 · doi:10.1007/s13300-025-01704-z
- Yabe D, Kawamori D, Seino Y, et al. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023;25(2):398-406. PubMed 36184780 · PMC10092154 · doi:10.1111/dom.14882
- Pieber TR, Svehlikova E, Urva S, et al. Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide. Front Endocrinol (Lausanne). 2025;16:1627947. PubMed 40964167 · PMC12436105 · doi:10.3389/fendo.2025.1627947